These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

248 related articles for article (PubMed ID: 33097315)

  • 1. Commentary on the impact of the COVID-19 pandemic on opioid use disorder treatment among Indigenous communities in the United States and Canada.
    Wendt DC; Marsan S; Parker D; Lizzy KE; Roper J; Mushquash C; Venner KL; Lam A; Swansburg J; Worth N; Sorlagas N; Quach T; Manoukian K; Bernett P; Radin SM
    J Subst Abuse Treat; 2021 Feb; 121():108165. PubMed ID: 33097315
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Leveraging pharmacists to maintain and extend buprenorphine supply for opioid use disorder amid COVID-19 pandemic.
    Peckham AM; Ball J; Colvard MD; Dadiomov D; Hill LG; Nichols SD; Tallian K; Ventricelli DJ; Tran TH
    Am J Health Syst Pharm; 2021 Mar; 78(7):613-618. PubMed ID: 33411894
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Characteristics and correlates of U.S. clinicians prescribing buprenorphine for opioid use disorder treatment using expanded authorities during the COVID-19 pandemic.
    Jones CM; Diallo MM; Vythilingam M; Schier JG; Eisenstat M; Compton WM
    Drug Alcohol Depend; 2021 Aug; 225():108783. PubMed ID: 34049102
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Leveraging COVID-19 to sustain regulatory flexibility in the treatment of opioid use disorder.
    Stringer KL; Langdon KJ; McKenzie M; Brockmann B; Marotta P
    J Subst Abuse Treat; 2021 Apr; 123():108263. PubMed ID: 33612196
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Using telehealth to improve buprenorphine access during and after COVID-19: A rapid response initiative in Rhode Island.
    Clark SA; Davis C; Wightman RS; Wunsch C; Keeler LAJ; Reddy N; Samuels EA
    J Subst Abuse Treat; 2021 May; 124():108283. PubMed ID: 33771282
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Characteristics and prescribing practices of clinicians recently waivered to prescribe buprenorphine for the treatment of opioid use disorder.
    Jones CM; McCance-Katz EF
    Addiction; 2019 Mar; 114(3):471-482. PubMed ID: 30194876
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Telemedicine increases access to buprenorphine initiation during the COVID-19 pandemic.
    Wang L; Weiss J; Ryan EB; Waldman J; Rubin S; Griffin JL
    J Subst Abuse Treat; 2021 May; 124():108272. PubMed ID: 33771276
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Medication treatment for opioid use disorder and community pharmacy: Expanding care during a national epidemic and global pandemic.
    Cochran G; Bruneau J; Cox N; Gordon AJ
    Subst Abus; 2020; 41(3):269-274. PubMed ID: 32697171
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Patient Satisfaction With Medications for Opioid Use Disorder Treatment via Telemedicine: Brief Literature Review and Development of a New Assessment.
    Cole TO; Robinson D; Kelley-Freeman A; Gandhi D; Greenblatt AD; Weintraub E; Belcher AM
    Front Public Health; 2020; 8():557275. PubMed ID: 33553083
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Co-Constructing a Community-Based Telemedicine Program for People With Opioid Use Disorder During the COVID-19 Pandemic: Lessons Learned and Implications for Future Service Delivery.
    Høj SB; de Montigny C; Chougar S; Léandre R; Beauchemin-Nadeau MÈ; Boyer-Legault G; Goyette A; Lamont SK; Bruneau J
    JMIR Public Health Surveill; 2023 Jul; 9():e39236. PubMed ID: 37494097
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Methadone Access for Opioid Use Disorder During the COVID-19 Pandemic Within the United States and Canada.
    Joudrey PJ; Adams ZM; Bach P; Van Buren S; Chaiton JA; Ehrenfeld L; Guerra ME; Gleeson B; Kimmel SD; Medley A; Mekideche W; Paquet M; Sung M; Wang M; You Kheang ROO; Zhang J; Wang EA; Edelman EJ
    JAMA Netw Open; 2021 Jul; 4(7):e2118223. PubMed ID: 34297070
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Adaptations to jail-based buprenorphine treatment during the COVID-19 pandemic.
    Duncan A; Sanders N; Schiff M; Winkelman TNA
    J Subst Abuse Treat; 2021 Feb; 121():108161. PubMed ID: 33371945
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Rethinking Opioid Dose Tapering, Prescription Opioid Dependence, and Indications for Buprenorphine.
    Chou R; Ballantyne J; Lembke A
    Ann Intern Med; 2019 Sep; 171(6):427-429. PubMed ID: 31450240
    [No Abstract]   [Full Text] [Related]  

  • 14. Use of Buprenorphine to Treat Opioid Use Disorder.
    Bartholow LAM; Pope J
    J Psychosoc Nurs Ment Health Serv; 2018 Nov; 56(11):9-12. PubMed ID: 30383881
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Opioid Use Disorder and COVID-19: Crashing of the Crises.
    Khatri UG; Perrone J
    J Addict Med; 2020; 14(4):e6-e7. PubMed ID: 32404651
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Growth and Distribution of Buprenorphine-Waivered Providers in the United States, 2007-2017.
    McBain RK; Dick A; Sorbero M; Stein BD
    Ann Intern Med; 2020 Apr; 172(7):504-506. PubMed ID: 31905379
    [No Abstract]   [Full Text] [Related]  

  • 17. A health crisis within a health crisis: Opioid access in the COVID-19 pandemic.
    Narayan A; Balkrishnan R
    Subst Abus; 2021; 42(2):148-152. PubMed ID: 33849399
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Test of a workforce development intervention to expand opioid use disorder treatment pharmacotherapy prescribers: protocol for a cluster randomized trial.
    Molfenter T; Knudsen HK; Brown R; Jacobson N; Horst J; Van Etten M; Kim JS; Haram E; Collier E; Starr S; Toy A; Madden L
    Implement Sci; 2017 Nov; 12(1):135. PubMed ID: 29141653
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Treatment of opioid use disorder during COVID-19: Experiences of clinicians transitioning to telemedicine.
    Uscher-Pines L; Sousa J; Raja P; Mehrotra A; Barnett M; Huskamp HA
    J Subst Abuse Treat; 2020 Nov; 118():108124. PubMed ID: 32893047
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Payer strategies to ensure access to care for individuals with opioid use disorder during COVID-19.
    Bachireddy C; Terplan M
    Am J Manag Care; 2021 Mar; 27(3):91-92. PubMed ID: 33720664
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.